Global Glioblastoma Multiforme Treatment Market Report and Forecast 2024-2032

Global Glioblastoma Multiforme Treatment Market Outlook

The global glioblastoma multiforme treatment market size was valued at USD 2.49 billion in 2023, driven by the increasing incidence of brain tumours across the globe. The market size is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032 to achieve a value of USD 5.15 billion by 2032.

Glioblastoma Multiforme Treatment: Introduction

Glioblastoma (GBM), commonly known as a grade IV astrocytoma, is an aggressive brain tumour that grows quickly. GBMs can develop from lower grade astrocytomas or develop from new brain tumours. The cerebral hemispheres of adults, particularly the frontal and temporal lobes, are where GBM develops most frequently. GBM is a deadly brain cancer that, if left untreated, can cause death in as little as six months.

Technologically advanced imaging techniques can be used to accurately pinpoint the location of brain tumours, such as computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI). Glioblastoma multiforme is often treated with surgery to remove as many tumours as feasible without harming the surrounding healthy brain tissue, then by radiation and chemotherapy. Most of the time, a craniotomy is used by surgeons to access the tumor site. The current standard of care for this illness is chemotherapy using the medication temozolomide. There are some types of brain tumours that are treated with temozolomide.

Global Glioblastoma Multiforme Treatment Market Analysis

The global market for glioblastoma multiforme treatment is witnessing significant growth due to the increasing focus towards developing better treatment options for patients which are affordable and convenient. The increasing number of approvals to conduct clinical studies to observe the complications associated with the condition and finding effective solutions are also influencing the market growth. These increasing approvals are directly contributing to the rise in number of clinical studies, providing hefty opportunities to develop and produce effective drugs for key players in the market especially cancer chemotherapy-based companies, further propelling the glioblastoma multiforme treatment market growth.

The increasing advancement in clinical imaging technologies such as computerized tomography (CT scan), and magnetic resonance imaging MRI are also enhancing the diagnosis process for glioblastoma multiforme with accuracy. The increasing contribution by the regional and state governments in the form of taking multiple initiatives to make sure that the treatment for such medical conditions is more accessible and affordable for everyone is also a major trend in the market. Due to the approvals followed by successful completion of clinical trials, pharmaceutical companies and other key players are constantly launching new, improved products and drugs that are helpful in curing glioblastoma multiforme, further boosting the global glioblastoma multiforme treatment market expansion.

Additionally, the FDA has approved the initiation of conducting a phase 2 clinical trial associated with assessing the safety and efficacy of azeliragon (previously TTP488) in patients with newly diagnosed unmethylated glioblastoma (GBM). Azeliragon is a pill which is taken once-a-day and administered orally. In January 2024, azeliragon was granted an orphan drug designation from the FDA for the treatment of GBM.

Global Glioblastoma Multiforme Treatment Market Segmentations

Market Breakup by Therapy

• Chemotherapy

• Radiation Therapy

• Other Treatments

Market Breakup by End User

• Hospitals

• Ambulatory Services

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Glioblastoma Multiforme Treatment Market Overview

The growth of the market is driven by the increasing burden of geriatric population, as people aged 60 and above are more susceptible to glioblastoma multiforme. Brain and other nervous system cancer is the tenth leading cause of death for men and women globally. The increasing incidence of brain tumours is primarily driving the demand for treatment. The increasing research studies, observations, and clinical trials about finding the potential of some drugs, such as Azeliragon, in the application against glioblastoma multiforme treatment are some major factors escalating the global glioblastoma multiforme treatment market development. The increasing approval for novel therapy and combination therapy for the treatment of glioblastoma multiforme is also driving the market growth.

North America is expected to lead the market throughout forecast period of 2024-2032. According to data statistics released by the American Society of Clinical Oncology (ASCO), nearly 24,810 adults (14,280 men and 10,530 women) are expected to be diagnosed with primary cancerous tumours of the brain and spinal cord in United States. The increase in new cancer cases associated with brain tumour will be responsible for increased research and development activities in the region and increase in manufacturing of drugs by the key players are also expected to drive the market growth.

Additionally, in 2024, it is predicted that primary cancerous brain and CNS tumours will be the leading cause of 18,990 deaths (11,020 men and 7,970 women). A projected 251,329 people worldwide passed away from primary CNS and brain tumours in 2020. For those under the age of 15, the relative 5-year survival rate is almost 75%. The relative 5-year survival rate for those aged 15 to 39 is quite close to 72%. For those over the age of 40, the 5-year relative survival rate is 21%.

Glioblastoma Multiforme Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Arbor Pharmaceuticals

• Bristol-Myers Squibb

• Eli Lilly and Company

• F. Hoffmann-La Roche Ltd

• Merck & Co. Inc.

• Sun Pharmaceutical Industries Ltd.

• Lanthen Pharmaceutical

• Pfizer Inc.

• Amgen Inc.

• Teva Pharmaceutical Industries Ltd.

Key Highlights of the Report